about
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemiaThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersResistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferasePhase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsA class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents.Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.Modified fatty acids and their possible therapeutic targets in malignant diseases.Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.Critical functions of RhoB in support of glioblastoma tumorigenesisMouse models of tuberous sclerosis complex.Novel agents in epithelial ovarian cancer.Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomasInhibition of farnesyltransferase: a rational approach to treat cancer?Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling.Small molecules and targeted therapies in distant metastatic disease.Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase.Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum.High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer.
P2860
Q24805262-6F0C1288-AB61-4ECB-BB4C-45D258ADA3B4Q26747403-2D6EC6F6-4458-47CA-A814-C6AEF3BCFE14Q27641065-669636DA-7632-46A9-B7E1-A0E2C57F5506Q33201555-2930B4D5-0B29-4219-BBCF-E19F180636FDQ33377668-6E927FDE-2490-4EA4-823B-02AB8B9A4EA4Q34391586-1154E1F7-ACBB-495C-B96B-8E5741C5E1C2Q34659415-50D1DED8-6D3E-4D10-BCC5-57F3DDF27E0AQ35091519-D45B44F6-37B6-4157-80D1-B692CB6628C0Q35186888-4BCA7A2F-5CAC-4FEF-A438-A26FC86ACBB8Q35213124-346ADAB4-84EA-4248-90D3-B8A66DF818F7Q35537914-E92582AF-6297-40ED-BDEA-B23428E822F4Q35609713-3FEF6C35-2BD5-46B7-B307-F5F39FE91F59Q35788796-87589A8C-B779-43FD-9C1F-2FD3C7B32667Q35962483-0802DBFB-E9BF-4D0D-BF4C-902CFFA8804BQ35968752-E7C745FB-74B0-494E-9651-41252DF608B0Q36327729-344F00F7-DF1F-48B5-A54C-9B08EF19B0EFQ36693797-32A6F82F-576B-45FC-8E6A-534F692EC7B4Q36828655-A2E87EFA-E42E-4419-872F-D33B240354BAQ37327005-2B8EB541-2A3D-4FD8-9206-979B3022173DQ37555793-EDFC535F-11B9-494E-BAD1-BF55C7403515Q37758841-445BBDD0-B833-4DBF-A3E9-D0ACE76F725CQ40478997-5EF99E57-AB25-4855-82B3-6A926C160109Q40507130-DC34EED8-1321-4BCB-87C4-B2C8DB5E4624Q40624857-302701DF-9AF0-4110-8DB5-752C6CEA5EB5Q42465607-10FB5D86-C0F7-422F-90E1-AFA634256908Q44645852-5A337A78-E927-4D81-8025-7DBA8781C8E9Q45135612-2A1DCDD4-34D1-400D-9368-366060705619Q45231874-42932D99-5232-438B-81CB-7A3C2884251EQ55021702-7A0E65DB-726B-49C8-99E2-588E595D67B4
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Farnesyl transferase inhibitors as anticancer agents.
@ast
Farnesyl transferase inhibitors as anticancer agents.
@en
Farnesyl transferase inhibitors as anticancer agents.
@nl
type
label
Farnesyl transferase inhibitors as anticancer agents.
@ast
Farnesyl transferase inhibitors as anticancer agents.
@en
Farnesyl transferase inhibitors as anticancer agents.
@nl
prefLabel
Farnesyl transferase inhibitors as anticancer agents.
@ast
Farnesyl transferase inhibitors as anticancer agents.
@en
Farnesyl transferase inhibitors as anticancer agents.
@nl
P2093
P1476
Farnesyl transferase inhibitors as anticancer agents.
@en
P2093
P304
P356
10.1016/S0959-8049(02)00166-1
P577
2002-09-01T00:00:00Z